Skip to main content

Harvard Bioscience, Inc.

corporate_fare Company Profile

Harvard Bioscience, Inc.

HBIO·NASDAQ·Industrial Applications And Services·CIK 0001123494

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing for pharmaceutical and therapy development. The company sells its products and services globally to academic institutions, government laboratories, and pharmaceutical, biotechnology, and contract research organizations (CROs). Harvard Bioscience operates in the United States, Europe, and China, utilizing both direct and distribution channels to reach customers worldwide. The business began in 1901 as Harvard Apparatus, founded by Dr. William T. Porter. Early inventions included ventilators based on Dr. Porter's design, the mechanical syringe pump in the 1950s, and the microprocessor-controlled syringe pump in the 1980s. Harvard Bioscience, Inc. was incorporated in Delaware in September 2000 and became the successor to Harvard Apparatus, Inc. in November 2000. In 2018, the company acquired Data Sciences International, Inc. (DSI), a global leader in products, services, and solutions for preclinical testing. The DSI product portfolio complements Harvard Bioscience's cellular and molecular technology (CMT) product portfolio, expanding its offerings from research and discovery to preclinical testing, with primary applications in drug and therapy testing.

Harvard Bioscience, Inc. (NASDAQ:HBIO) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 28 items for HBIO at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • 1-for-10 Reverse Stock Split Announced by Harvard Bioscience, Effective March 16
  • Harvard Bioscience Finalizes 1-for-10 Reverse Stock Split to Regain Nasdaq Compliance
  • Harvard Bioscience Reports Strong Preliminary Q4 Results, Outlines Growth Strategy for 2026
  • Final Prospectus Filed for Resale of 9.5 Million Shares by Selling Securityholders
  • Shareholders to Vote on Reverse Stock Split to Maintain Nasdaq Listing

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$86.55M
Net Income
-$56.7M
Diluted EPS
-$1.28
Op. Cash Flow
$6.73M
Free Cash Flow
$5.47M
Gross Profit
$49.91M
Operating Income
-$48.58M
Cash & Equivalents
$8.61M
Total Debt
$35.87M
Debt / Equity
2.61×
Net Margin
-65.5%
Shares Outstanding
44.72M sh
Source: 10-K · filed 2026-03-13 · accession 0001171843-26-001548
$8.49 -1.96% today
52-week range · as of 2026-11-10 $4 – $9.6
Market cap
$39.6M
Volume
22.7K (0.9× avg)
3-mo avg 26K
Live data · 2026-11-22 08:00 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed HBIO - Filings & News (Page 2)

HBIO
Mar 06, 2026, 6:23 PM EST
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $0.4947
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Mar 06, 2026, 4:01 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.4567
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Feb 10, 2026, 7:30 AM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.540
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Feb 09, 2026, 4:03 PM EST
Filing Type: 424B3
Importance Score:
9
Price at Filing: $0.5301
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Jan 30, 2026, 5:15 PM EST
Filing Type: DEF 14A
Importance Score:
8
Price at Filing: $0.4901
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Jan 30, 2026, 5:02 PM EST
Filing Type: S-3
Importance Score:
8
Price at Filing: $0.4901
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Jan 29, 2026, 4:30 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.5341
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
HBIO
Jan 20, 2026, 5:04 PM EST
Filing Type: PRE 14A
Importance Score:
8
Price at Filing: $0.5821
Real-time Price: $8.49 info
Change: Reverse Stock Split info
Market Cap: $39.603M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets